Research Papers

25 of 55 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery.
Han G; Noh D; Lee H; Lee S; Kim S; Yoon HY; Lee SH.
Adv Drug Deliv Rev (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
Kang DD; Li H; Dong Y.
Adv Drug Deliv Rev (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Imaging drug delivery to the lungs: Methods and applications in oncology.
Man F; Tang J; Swedrowska M; Forbes B; T M de Rosales R.
Adv Drug Deliv Rev (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Targeting the liver in dementia and cognitive impairment: Dietary macronutrients and diabetic therapeutics.
Hunt NJ; Wahl D; Westwood LJ; Lockwood GP; Le Couteur DG; Cogger VC.
Adv Drug Deliv Rev (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
In vivo fate and intracellular trafficking of vaccine delivery systems.
Lee J; Kim D; Byun J; Wu Y; Park J; Oh YK.
Adv Drug Deliv Rev (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Targeting vascular inflammation through emerging methods and drug carriers.
Nong J; Glassman PM; Muzykantov VR.
Adv Drug Deliv Rev (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.
Aldarondo D; Wayne E.
Adv Drug Deliv Rev (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic.
Ljubimov VA; Ramesh A; Davani S; Danielpour M; Breunig JJ; Black KL.
Adv Drug Deliv Rev (Unknown)
Published: 2021
1/6 Transparent
Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting th…
Minnaert AK; Vanluchene H; Verbeke R; Lentacker I; De Smedt SC; Raemdonck K; Sanders NN; Remaut K.
Adv Drug Deliv Rev (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Prophylactic vaccine delivery systems against epidemic infectious diseases.
Pan C; Yue H; Zhu L; Ma GH; Wang HL.
Adv Drug Deliv Rev (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical t…
Batis N; Brooks JM; Payne K; Sharma N; Nankivell P; Mehanna H.
Adv Drug Deliv Rev (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19.
Brain D; Plant-Hately A; Heaton B; Arshad U; David C; Hedrich C; Owen A; Liptrott NJ.
Adv Drug Deliv Rev (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
A call for the standardised reporting of factors affecting the exogenous loading of extracellular vesicles with therape…
Rankin-Turner S; Vader P; O'Driscoll L; Giebel B; Heaney LM; Davies OG.
Adv Drug Deliv Rev (Unknown)
Published: 2021
4/6 Transparent
Data Funding Declared
Adaptive immune responses to SARS-CoV-2.
Forthal D.
Adv Drug Deliv Rev (Unknown)
Published: 2021
1/6 Transparent
Current and prospective computational approaches and challenges for developing COVID-19 vaccines.
Hwang W; Lei W; Katritsis NM; MacMahon M; Chapman K; Han N.
Adv Drug Deliv Rev (Unknown)
Published: 2021
4/6 Transparent
Data Funding Declared
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty S; Mallajosyula V; Tato CM; Tan GS; Wang TT.
Adv Drug Deliv Rev (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Nanocarrier vaccines for SARS-CoV-2.
Machhi J; Shahjin F; Das S; Patel M; Abdelmoaty MM; Cohen JD; Singh PA; Baldi A; Bajwa N; Kumar R; Vora LK; Patel TA; Oleynikov MD; Soni D; Yeapuri P; Mukadam I; Chakraborty R; Saksena CG; Herskovitz J; Hasan M; Oupicky D; Das S; Donnelly RF; Hettie KS; Chang L; Gendelman HE; Kevadiya BD.
Adv Drug Deliv Rev (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA.
Adv Drug Deliv Rev (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Self-assembled mRNA vaccines.
Kim J; Eygeris Y; Gupta M; Sahay G.
Adv Drug Deliv Rev (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Peptide and peptide-based inhibitors of SARS-CoV-2 entry.
Schütz D; Ruiz-Blanco YB; Münch J; Kirchhoff F; Sanchez-Garcia E; Müller JA.
Adv Drug Deliv Rev (Unknown)
Published: 2020
3/6 Transparent
Data Funding Declared
Engineered tissues and strategies to overcome challenges in drug development.
Khalil AS; Jaenisch R; Mooney DJ.
Adv Drug Deliv Rev (Unknown)
Published: 2020
1/6 Transparent
Funding Declared
Micro and nanoscale technologies in oral drug delivery.
Ahadian S; Finbloom JA; Mofidfar M; Diltemiz SE; Nasrollahi F; Davoodi E; Hosseini V; Mylonaki I; Sangabathuni S; Montazerian H; Fetah K; Nasiri R; Dokmeci MR; Stevens MM; Desai TA; Khademhosseini A.
Adv Drug Deliv Rev (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Lipid nanoparticle technology for therapeutic gene regulation in the liver.
Witzigmann D; Kulkarni JA; Leung J; Chen S; Cullis PR; van der Meel R.
Adv Drug Deliv Rev (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Controlling timing and location in vaccines.
Irvine DJ; Aung A; Silva M.
Adv Drug Deliv Rev (Unknown)
Published: 2020
1/6 Transparent
Funding Declared
Inhalation delivery technology for genome-editing of respiratory diseases.
Chow MYT; Chang RYK; Chan HK.
Adv Drug Deliv Rev (Unknown)
Published: 2020
1/6 Transparent
Funding Declared